Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 88000 shares trading hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Price Performance
The company has a quick ratio of 0.46, a current ratio of 0.07 and a debt-to-equity ratio of 138.88. The company has a market cap of C$1.33 million, a PE ratio of -1.00 and a beta of -0.02. The firm has a 50 day simple moving average of C$0.01 and a 200-day simple moving average of C$0.01.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- What Do S&P 500 Stocks Tell Investors About the Market?
- FedEx Delivers Another Crushing Blow to Its Stock Price
- About the Markup Calculator
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- ETF Screener: Uses and Step-by-Step Guide
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
